Connection
Kristina Brooks to Antiviral Agents
This is a "connection" page, showing publications Kristina Brooks has written about Antiviral Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.238 |
|
|
|
-
Schwab SK, Roon LE, Bushman LR, Coyle RP, Johnson BM, Ellison LA, Anderson PL, Brooks KM. Application of an intracellular LC-MS/MS assay for the determination of carbovir-triphosphate and remdesivir-triphosphate in peripheral blood mononuclear cells and dried blood spots. J Pharm Biomed Anal. 2027 Jan 15; 283:117728.
Score: 0.628
-
Brooks KM, Baltrusaitis K, Clarke DF, Nachman S, Jao J, Purswani MU, Agwu A, Beneri C, Deville JG, Powis KM, Stek AM, Eke AC, Shapiro DE, Capparelli E, Greene E, George K, Yin DE, Jean-Philippe P, Chakhtoura N, Bone F, Bacon K, Johnston B, Reding C, Kersey K, Humeniuk R, Best BM, Mirochnick M, Momper JD. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. J Infect Dis. 2024 Oct 16; 230(4):878-888.
Score: 0.550
-
Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. J Antimicrob Chemother. 2019 08 01; 74(8):2360-2364.
Score: 0.383
-
Vyshenska D, Reed JC, Roychoudhury P, Zheng L, Olefsky M, Ritz J, McCarthy C, Saha PT, Hao L, Mills MG, Shea A, Nunley BE, Javan AC, Brooks KM, Nachman S, Eron J, Gandhi RT, Currier J, Fischer WA, Zucker J, Wilkin T, Greninger AL. Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial. Lancet Microbe. 2026 Sep; 7(9):101464.
Score: 0.156
-
Chappell CA, Brooks KM, Kiser JJ, Klein B, Nerguizian D, Bushman L, Laird HJ, Stewart E, Kasula K, Kwon KM, Letterio C, Naik S, Kreter B, Krans EE. Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women With Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: A Pharmacokinetic Study. Clin Infect Dis. 2026 07 08; 82(6):993-996.
Score: 0.155
-
Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clin Infect Dis. 2025 04 30; 80(4):744-751.
Score: 0.143
-
Brooks KM, Pinilla M, Stek AM, Shapiro DE, Barr E, Febo IL, Paul ME, Deville JG, George K, Knowles K, Rungruengthanakit K, Browning R, Chakhtoura N, Capparelli EV, Mirochnick M, Best BM. Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. J Acquir Immune Defic Syndr. 2022 07 01; 90(3):343-350.
Score: 0.117
-
Beigel JH, Voell J, Muñoz P, Kumar P, Brooks KM, Zhang J, Iversen P, Heald A, Wong M, Davey RT. Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation. Br J Clin Pharmacol. 2018 Jan; 84(1):25-34.
Score: 0.084
-
Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, Alfaro RM, Nghiem K, Lozier J, Hadigan C, Penzak SR. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 11; 61(11).
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|